RECRUITING

Lipoprotein Kinetics in T1D

Talk to us

Conditions

Type 1 Diabetes

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.

Official Title

Apolipoprotein C3-loading of Apolipoprotein B100 Lipoproteins and Cardiovascular Disease in Patients with Type 1 Diabetes

Quick Facts

Study Start:2022-05-09
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05179954

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age: ≥18 but ≤45 years
  2. * premenopausal/eumenorrheic and not pregnant or breastfeeding
  3. * non-obese (body mass index ≥18.5\<30.0 kg/m2)
  4. * Fasting plasma triglyceride \<150 mg/dL
  5. * Fasting plasma glucose \<100 mg/dL
  6. * Plasma glucose 2 h after a 75 g oral glucose challenge \<140 mg/dL
  7. * HbA1c \<5.6%.
  8. * stable insulin regimen (multiple daily insulin injections or continuous subcutaneous insulin) for at least 8 weeks before screening
  9. * no use of diabetes medications other than insulin
  10. * HbA1c \<6.5%, basal (overnight fasted)
  11. * no severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or a medical facility in the 6 months prior to screening or metabolic testing
  1. * more than 1.5 h of structured exercise/week
  2. * use of tobacco products, excessive amounts of alcohol, or dietary supplements and/or medications known to affect lipid metabolism
  3. * hypothyroidism or other disorders known to affect lipid metabolism
  4. * conditions that would make it impossible to complete the study protocol

Contacts and Locations

Study Contact

Amanda Heider
CONTACT
(573) 884-6852
ahmc4@health.missouri.edu
Mittendorfer Lab
CONTACT
MittendorferLab@umsystem.edu

Principal Investigator

Bettina Mittendorfer
PRINCIPAL_INVESTIGATOR
University of Missouri-Columbia

Study Locations (Sites)

University of Missouri School of Medicine
Columbia, Missouri, 65212
United States

Collaborators and Investigators

Sponsor: University of Missouri-Columbia

  • Bettina Mittendorfer, PRINCIPAL_INVESTIGATOR, University of Missouri-Columbia

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-09
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2022-05-09
Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Type 1 Diabetes